TACSTD2 and neoplasm: Higher expression of TROP-2 was associated with the clinicopathological characteristics of poor histological differentiation (58.18% vs. 37.56%, p < 0.0001), T3–T4 tumor depth (40% vs. 53.38%, p = 0.0003), lymph node metastasis (57.43% vs. 36.97%, p < 0.0001) and lymphatic (54.8% vs. 34.42%, p < 0.0001) and venous invasion (68.57% vs. 41.49%, p < 0.0001) [22].